Search

CN-122005639-A - Application of composition containing mucin-containing Acremonium and silybum marianum in liver protection product

CN122005639ACN 122005639 ACN122005639 ACN 122005639ACN-122005639-A

Abstract

The invention belongs to the technical field of nutritional compositions and biological medicines, and particularly relates to application of a composition containing mucin-containing Acremonium and silybum marianum in liver protection products. The composition provided by the invention comprises the akkermansia muciniphila (AKKERMANSIA MUCINIPHILA) and the silybum marianum extract, wherein the weight ratio of the akkermansia muciniphila to the silybum marianum extract is 1-3:1-10. The composition can be used for preparing liver protection products, including functional foods or health care products with auxiliary protection effect on chemical liver injury, and medicines for preventing and treating alcoholic liver injury, chemical liver injury and the like. Compared with single component, the composition has better effect on protecting liver, and can synergistically play the roles of protecting liver cells, regulating intestinal tract-liver axis and the like.

Inventors

  • YUE ZHONGBAO
  • LIU FEITONG
  • ZHAO LINGLING
  • LI TENGJI
  • ZHAO FEI
  • HUANG JINGYA
  • CHEN JIECHUN

Assignees

  • 合生元（广州）健康产品有限公司
  • 健合香港有限公司

Dates

Publication Date
20260512
Application Date
20251230

Claims (18)

  1. 1. A composition is characterized in that the composition has liver protection effect, the composition consists of akkermansia muciniphila (AKKERMANSIA MUCINIPHILA) and silybum marianum extract, and the weight ratio of the akkermansia muciniphila to the silybum marianum extract is 1-3:1-10.
  2. 2. The composition according to claim 1, wherein the mass ratio of the akkermansia muciniphila to the silybum marianum extract is 1-2:3.5-10.
  3. 3. The composition of claim 1, wherein the composition comprises, the mucin the ackermanni bacteria include: live and/or inactivated bacteria of akkermansia muciniphila.
  4. 4. The composition of claim 3, wherein the viable bacteria is at a concentration of 1X 10 11 -1×10 12 CFU/g and the inactivated bacteria is at a concentration of 1X 10 11 -1×10 12 TFU/g.
  5. 5. The liver protecting composition according to claim 4, wherein the concentration of the living bacteria is 2X 10 11 CFU/g and the concentration of the inactivated bacteria is 2X 10 11 TFU/g.
  6. 6. The composition of claim 1, wherein the akkermansia muciniphila comprises any one or more of AKK PROBIO, AKKERMANSIA MUCT TM , akk 11.
  7. 7. The method of preparing the composition according to any one of claims 1 to 6, wherein the method comprises mixing the extract of Alkermansia muciniphila and Silybum marianum in a weight ratio.
  8. 8. Use of a composition according to any one of claims 1-6 for the preparation of a liver protection product.
  9. 9. The use of claim 8, wherein the liver protection product comprises any one or more of the following: (1) Functional food or health product with auxiliary protection effect on chemical liver injury; (2) A medicament for preventing or treating liver injury, wherein the liver injury comprises any one or more of alcoholic liver injury, chemical liver injury, non-alcoholic fatty liver injury and autoimmune liver injury.
  10. 10. A functional food is characterized in that, the functional food comprises the composition of any one of claims 1-6.
  11. 11. The functional food according to claim 10, wherein said functional food comprises a liquid, solid or semi-solid dosage form.
  12. 12. The functional food according to claim 10, wherein said functional food further comprises a nutritionally acceptable nutrient.
  13. 13. A health product comprising the composition of any one of claims 1-6.
  14. 14. The health product according to claim 13, wherein the dosage form of the health product comprises a tablet, capsule, soft capsule, granule, pill, gel candy, powder, oral liquid or drop.
  15. 15. The health product according to claim 14, wherein, the health care product also comprises a nutritionally acceptable nutritional additive.
  16. 16. A pharmaceutical product, characterized in that it comprises a composition according to any one of claims 1-6.
  17. 17. The pharmaceutical product according to claim 16, wherein the pharmaceutical product comprises any one or more of a tablet, a pill, a powder, a suspension, a gel, an emulsion, a cream, a granule, a capsule, a suppository, an injection, a spray, and an injection.
  18. 18. The pharmaceutical product of claim 16, wherein the pharmaceutical product comprises, the medicine also comprises pharmaceutically acceptable auxiliary materials.

Description

Application of composition containing mucin-containing Acremonium and silybum marianum in liver protection product Technical Field The invention belongs to the technical field of nutritional compositions and biological medicines, and particularly relates to application of a composition containing mucin-containing Acremonium and silybum marianum in liver protection products. Background The liver is used as a core organ for metabolism, detoxification and immunoregulation of human body, and plays key physiological roles of substance conversion, toxin removal, nutrition storage and the like, and the health state of the liver directly influences the whole metabolic balance and life activities of the human body. With the change of modern life style, the incidence of liver injury caused by excessive intake of alcohol, high-fat and high-sugar diet, chemical drug abuse, environmental toxin exposure and other factors is rising year by year, and has become a great challenge in the field of global public health. Clinically common liver injury types include alcoholic liver injury (ALD), non-alcoholic fatty liver injury (NAFLD), chemical liver injury (such as drug and poison induction), autoimmune liver injury and the like, and if the injury is not effectively intervened for a long time, the injury can gradually progress to fatty liver, liver fibrosis, liver cirrhosis and even liver cancer, and seriously threaten human health. At present, liver protection products in clinic and market are mainly divided into three types of chemical drugs, natural extract preparations and probiotic preparations, but all the three types of the liver protection products have obvious limitations that although chemical drugs such as polyene phosphatidylcholine, silybin compounds and the like can relieve liver injury to a certain extent, side effects can exist in long-term use, the targeting property of liver tissue repair is insufficient, single natural extracts (such as silybum marianum extracts) mainly play a role in protecting liver through antioxidation and anti-inflammatory effects, but the core problems of liver microecology unbalance and the like are difficult to improve, traditional probiotic preparations are focused on adjusting the integral structure of intestinal flora, and have limited liver protection effects due to lack of specific intervention targets aiming at liver-intestinal axis. In addition, the existing researches focus on the liver protection effect of a single component, the synergistic mechanism of different active components is not explored sufficiently, and the clinical requirements of high-efficiency and safe liver protection products are difficult to meet. The silybum marianum extract is a natural active ingredient extracted from seeds of silybum marianum of the Compositae, and the main active ingredient of the silybum marianum extract is silymarin (including flavonoid compounds such as silybin, silydianin and silybum marianum), has proved to have remarkable functions of resisting oxidization, inflammation and fibrosis and promoting liver cell repair and regeneration, and is one of the most widely used natural liver-protecting ingredients at present. Modern pharmacological studies show that silymarin can reduce chemical and alcoholic liver injury by removing Reactive Oxygen Species (ROS) in liver cells, inhibiting inflammatory factors (such as TNF-alpha and IL-6) release, regulating expression of genes related to lipid metabolism and the like, but has lower bioavailability, weaker regulation and control effect on liver injury mediated by intestinal flora and limited clinical application effects. Acremonium muciniphilum (AKKERMANSIA MUCINIPHILA) is an intestinal probiotic of interest in recent years, which is one of the dominant strains in the human intestinal flora, and is mainly colonized in the intestinal mucus layer, and participates in intestinal barrier function regulation, metabolic homeostasis maintenance and immune response regulation by degrading mucins. In recent years, research shows that the AKK strain is closely related to liver health, on one hand, the AKK strain can reduce liver inflammatory reaction by adjusting the composition of intestinal flora, enhancing the integrity of intestinal barrier and reducing endotoxin blood, and on the other hand, the metabolite (such as short-chain fatty acid) of the akkermansia muciniphila can regulate and control liver lipid metabolism through liver-intestinal axis, thereby reducing hepatic cell steatosis and having potential protection effect on nonalcoholic fatty liver and alcoholic liver injury. However, the intervention effect of single mucin-philin ackermanni on severe liver injury is still to be improved, and the synergistic effect of single mucin-philin ackermanni and natural liver protection components is not yet deeply excavated. Based on the current research situation, although the silybum marianum extract and the mucin-philic ackermannia have certain liv